专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

US20120195908A1 COMBINATORIAL THERAPY 有权
标题翻译：组合治疗
公开(公告)号：US20120195908A1
公开(公告)日：2012-08-02
申请号：US13171289
申请日：2011-06-28
申请人： Anan Chuntharapai , Gregory D. Plowman , Marc Tessier-Lavigne , Yan Wu , Weilan Ye
发明人： Anan Chuntharapai , Gregory D. Plowman , Marc Tessier-Lavigne , Yan Wu , Weilan Ye
IPC分类号： A61K39/395 , A61P7/00 , C12N9/96 , C07K16/28
CPC分类号： A61K39/3955 , A61K45/06 , A61K51/1093 , A61K2039/505 , A61K2039/507 , C07K16/22 , C07K16/2842 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/74
摘要： The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.
摘要翻译：本发明涉及VEGF拮抗剂和α5β1拮抗剂用于治疗癌症并抑制血管生成和/或血管通透性的用途，包括抑制疾病中的异常血管发生。本发明还涉及VEGFR激动剂和α5β1激动剂促进血管生成和血管通透性的用途。本发明还涉及新的抗α5β1抗体，包含它们的组合物和试剂盒以及制备和使用它们的方法。

22. 发明申请

US20090169542A1 Modulators of neuronal regeneration 有权
公开(公告)号：US20090169542A1
公开(公告)日：2009-07-02
申请号：US11983775
申请日：2007-11-09
申请人： Jasvinder Atwal , Marc Tessier-Lavigne
发明人： Jasvinder Atwal , Marc Tessier-Lavigne
IPC分类号： A61K39/395 , G01N33/53 , C12Q1/68 , C07K16/00 , C07K14/00 , C07H21/02 , C07H1/00 , A61K38/02 , A61K31/70 , A61K31/7088 , A61P25/00
CPC分类号： G01N33/5058 , G01N2500/02
摘要： The present invention provides methods and compositions related to CNS function and diseases.

23. 发明申请

US20090155928A1 Modulating robo: ligand interactions 审中-公开
标题翻译：调节robo：配体相互作用
公开(公告)号：US20090155928A1
公开(公告)日：2009-06-18
申请号：US11891963
申请日：2007-08-13
申请人： Corey S. Goodman , Thomas Kidd , Katja Brose , Marc Tessier-Lavigne
发明人： Corey S. Goodman , Thomas Kidd , Katja Brose , Marc Tessier-Lavigne
IPC分类号： G01N33/566 , C07K14/00 , C12N15/11
CPC分类号： C07K14/70503 , A61K38/00 , C07K14/4702 , G01N33/566 , G01N33/68 , G01N2333/43573 , G01N2500/02
摘要： Disclosed are methods and compositions for identifying agents which modulate the interaction of Robo and a Robo ligand and for modulating the interaction of Robo and a Robo ligand. The methods for identifying Robo:ligand modulators find particular application in commercial drug screens. These methods generally comprise (1) combining a Robo polypeptide, a Slit polypeptide and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and (2) determining a second interaction of the Robo and Slit polypeptides in the presence of the agent, wherein a difference between the first and second interactions indicates that the aget modulates the interaction of the Robo and Slit polypeptides. The subject methods of modulating the interaction of Robo and a Robo ligand involve combining a Robo polypeptide, a Slit polypeptide and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction. In a particular embodiment, the modulator is dominant negative form of the Robo or Slit polypeptide.
摘要翻译：公开了用于鉴定调节Robo和Robo配体的相互作用并调节Robo和Robo配体的相互作用的试剂的方法和组合物。用于鉴定Robo：配体调节剂的方法在商业药物筛选中发现具体应用。这些方法通常包括（1）在条件下组合Robo多肽，狭缝多肽和候选试剂，但是对于所述试剂的存在，所述Robo和狭缝多肽参与第一相互作用，和（2）确定第二相互作用的Robo和Slit多肽，其中所述第一和第二相互作用之间的差异指示所述琼脂调节所述Robo和Slit多肽的相互作用。调节Robo和Robo配体的相互作用的主题方法包括在条件下组合Robo多肽，狭缝多肽和调节剂，但是对于调节剂的存在，Robo和Slit多肽参与第一相互作用，由此 Robo和Slit多肽参与与第一相互作用不同的第二相互作用。在一个具体实施方案中，调节剂是Robo或Slit多肽的显性阴性形式。

24. 发明申请

US20050196783A1 Modulating Robo: ligand interactions 审中-公开
公开(公告)号：US20050196783A1
公开(公告)日：2005-09-08
申请号：US11022546
申请日：2004-12-23
申请人： Corey Goodman , Thomas Kidd , Katja Brose , Marc Tessier-Lavigne
发明人： Corey Goodman , Thomas Kidd , Katja Brose , Marc Tessier-Lavigne
IPC分类号： C12N15/09 , A61K38/00 , A61K38/17 , A61P43/00 , C07K14/47 , C07K14/705 , C07K16/18 , C12N15/12 , G01N33/15 , G01N33/50 , G01N33/566 , G01N33/68 , C12Q1/68 , A61K39/395 , C07H21/04 , C07K16/28 , G01N33/53 , G01N33/567
CPC分类号： C07K14/70503 , A61K38/00 , C07K14/4702 , G01N33/566 , G01N33/68 , G01N2333/43573 , G01N2500/02
摘要： Disclosed are methods and compositions for identifying agents which modulate the interaction of Robo and a Robo ligand and for modulating the interaction of Robo and a Robo ligand. The methods for identifying Robo:ligand modulators find particular application in commercial drug screens. These methods generally comprise (1) combining a Robo polypeptide, a Slit polypeptide and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and (2) determining a second interaction of the Robo and Slit polypeptides in the presence of the agent, wherein a difference between the first and second interactions indicates that the aget modulates the interaction of the Robo and Slit polypeptides. The subject methods of modulating the interaction of Robo and a Robo ligand involve combining a Robo polypeptide, a Slit polypeptide and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction. In a particular embodiment, the modulator is dominant negative form of the Robo or Slit polypeptide.

25. 发明授权

US06861228B2 Modulating Robo: ligand interactions 失效
标题翻译：调制Robo：配体相互作用
公开(公告)号：US06861228B2
公开(公告)日：2005-03-01
申请号：US10289776
申请日：2002-11-06
申请人： Corey S. Goodman , Thomas Kidd , Katja Brose , Marc Tessier-Lavigne
发明人： Corey S. Goodman , Thomas Kidd , Katja Brose , Marc Tessier-Lavigne
IPC分类号： C12N15/09 , A61K38/00 , A61K38/17 , A61P43/00 , C07K14/47 , C07K14/705 , C07K16/18 , C12N15/12 , G01N33/15 , G01N33/50 , G01N33/566 , G01N33/68 , G01N33/53 , A61K39/395
CPC分类号： C07K14/70503 , A61K38/00 , C07K14/4702 , G01N33/566 , G01N33/68 , G01N2333/43573 , G01N2500/02
摘要： Disclosed are methods and compositions for identifying agents which modulate the interaction of Robo and a Robo ligand and for modulating the interaction of Robo and a Robo ligand. The methods for identifying Robo:ligand modulators find particular application in commercial drug screens. These methods generally comprise (1) combining a Robo polypeptide, a Slit polypeptide and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and (2) determining a second interaction of the Robo and Slit polypeptides in the presence of the agent, wherein a difference between the first and second interactions indicates that the aget modulates the interaction of the Robo and Slit polypeptides. The subject methods of modulating the interaction of Robo and a Robo ligand involve combining a Robo polypeptide, a Slit polypeptide and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction. In a particular embodiment, the modulator is dominant negative form of the Robo or Slit polypeptide.
摘要翻译：公开了用于鉴定调节Robo和Robo配体的相互作用并调节Robo和Robo配体的相互作用的试剂的方法和组合物。用于鉴定Robo：配体调节剂的方法在商业药物筛选中发现具体应用。这些方法通常包括（1）在条件下组合Robo多肽，狭缝多肽和候选试剂，但是对于所述试剂的存在，所述Robo和狭缝多肽参与第一相互作用，和（2）确定第二相互作用的Robo和Slit多肽，其中所述第一和第二相互作用之间的差异指示所述琼脂调节所述Robo和Slit多肽的相互作用。调节Robo和Robo配体的相互作用的主题方法包括在条件下组合Robo多肽，狭缝多肽和调节剂，但是对于调节剂的存在，Robo和Slit多肽参与第一相互作用，由此 Robo和Slit多肽参与与第一相互作用不同的第二相互作用。在一个具体实施方案中，调节剂是Robo或Slit多肽的显性阴性形式。

26. 发明授权

US06623738B1 Semaphorin receptors 有权
标题翻译：信号素受体
公开(公告)号：US06623738B1
公开(公告)日：2003-09-23
申请号：US09439711
申请日：1999-11-12
申请人： Marc Tessier-Lavigne , Zhigang He , Hang Chen
发明人： Marc Tessier-Lavigne , Zhigang He , Hang Chen
IPC分类号： A61K39395
CPC分类号： C07K14/7056 , A61K38/00
摘要： The invention provides methods and compositions relating to two classes of semaphorin receptors, SR1 and SR2. The polypeptides may be produced recombinantly from transformed host cells from the disclosed SR encoding nucleic acids or purified from human cells. The invention provides isolated SR hybridization probes and primers, capable of specifically hybridizing with the disclosed SR genes. SR-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
摘要翻译：本发明提供了与两类信号素受体SR1和SR2相关的方法和组合物。可以从所公开的SR编码核酸的转化的宿主细胞重组产生多肽或从人细胞纯化。本发明提供了能够与所公开的SR基因特异性杂交的分离的SR杂交探针和引物。 SR特异性结合剂，例如特异性抗体，以及在诊断，治疗和生物制药工业中制备和使用本发明组合物的方法。

27. 发明授权

US06218526B1 Polynucleotide encoding human netrin-1 有权
标题翻译：编码人netrin-1的多核苷酸
公开(公告)号：US06218526B1
公开(公告)日：2001-04-17
申请号：US09136981
申请日：1998-08-20
申请人： Candace Swimmer , Anne Shyjan , David Leonardo , Yuan Zhang , Timothy Kennedy , Tito Serafini , Marc Tessier-Lavigne
发明人： Candace Swimmer , Anne Shyjan , David Leonardo , Yuan Zhang , Timothy Kennedy , Tito Serafini , Marc Tessier-Lavigne
IPC分类号： C12N1518
CPC分类号： C07K14/475 , A61K38/00
摘要： Specific netrin proteins, nucleic acids which encode netrin proteins and hybridization reagents, probes and primers capable of hybridizing with netrin genes and methods for screening chemical libraries for lead compounds for pharmacological agents useful in the diagnosis or treatment of disease associated undesirable cell growth are provided. An exemplary screen involves forming a mixture comprising a recombinant netrin protein, a natural intracellular netrin protein binding target, and a candidate pharmacological agent; incubating the mixture under conditions whereby, but for the presence of said candidate pharmacological agent, said netrin protein selectively binds said binding target; and detecting the presence or absence of specific binding of said netrin protein to said binding target.
摘要翻译：提供了特异性netrin蛋白质，编码netrin蛋白质的核酸和杂交试剂，能够与netrin基因杂交的探针和引物以及用于筛选用于诊断或治疗疾病相关的不希望的细胞生长的药物的铅化合物的化学文库的方法。示例性屏幕包括形成包含重组netrin蛋白质，天然细胞内netrin蛋白结合靶标和候选药理学试剂的混合物; 在这样的条件下孵育混合物，但是对于所述候选药理学试剂的存在，所述网蛋白选择性结合所述结合靶; 并检测所述网蛋白与所述结合靶的特异性结合的存在或不存在。

28. 发明授权

US5824775A Human netrin-1 失效
标题翻译：人类netrin-1
公开(公告)号：US5824775A
公开(公告)日：1998-10-20
申请号：US635137
申请日：1996-04-19
申请人： Candace Swimmer , Anne Shyjan , David Leonardo , Yuan Zhang , Timothy Kennedy , Tito Serafini , Marc Tessier-Lavigne
发明人： Candace Swimmer , Anne Shyjan , David Leonardo , Yuan Zhang , Timothy Kennedy , Tito Serafini , Marc Tessier-Lavigne
IPC分类号： C12N15/09 , A61K31/00 , A61K38/00 , A61K45/00 , A61P25/00 , C07K14/47 , C07K14/475 , C12N15/18 , C12Q1/68 , G01N33/15 , G01N33/50 , G01N33/566 , C07K1/00 , C07K14/00 , C07K17/00
CPC分类号： C07K14/475 , A61K38/00
摘要： Specific netrin proteins, nucleic acids which encode netrin proteins and hybridization reagents, probes and primers capable of hybridizing with netrin genes and methods for screening chemical libraries for lead compounds for pharmacological agents useful in the diagnosis or treatment of disease associated undesirable cell growth are provided. An exemplary screen involves forming a mixture comprising a recombinant netrin protein, a natural intracellular netrin protein binding target, and a candidate pharmacological agent; incubating the mixture under conditions whereby, but for the presence of said candidate pharmacological agent, said netrin protein selectively binds said binding target; and detecting the presence or absence of specific binding of said netrin protein to said binding target.
摘要翻译：提供了特异性netrin蛋白质，编码netrin蛋白质的核酸和杂交试剂，能够与netrin基因杂交的探针和引物以及用于筛选用于诊断或治疗疾病相关的不希望的细胞生长的药物的铅化合物的化学文库的方法。示例性屏幕包括形成包含重组netrin蛋白质，天然细胞内netrin蛋白结合靶标和候选药理学试剂的混合物; 在这样的条件下孵育混合物，但是对于所述候选药理学试剂的存在，所述网蛋白选择性结合所述结合靶; 并检测所述网蛋白与所述结合靶的特异性结合的存在或不存在。

29. 发明申请

US20100047232A1 MODULATORS OF NEURONAL REGENERATION 审中-公开
标题翻译：神经再生的调节剂
公开(公告)号：US20100047232A1
公开(公告)日：2010-02-25
申请号：US12208883
申请日：2008-09-11
申请人： Jasvinder Atwal , Marc Tessier-Lavigne
发明人： Jasvinder Atwal , Marc Tessier-Lavigne
IPC分类号： A61K39/395 , G01N33/53 , C07K14/00 , C07K2/00 , C07H21/02 , A61P25/00
CPC分类号： G01N33/5058 , G01N2500/02
摘要： The present invention provides methods and compositions related to CNS function and diseases.
摘要翻译：本发明提供了与CNS功能和疾病有关的方法和组合物。

30. 发明申请

US20090220504A1 COMBINATORIAL THERAPY 审中-公开
标题翻译：组合治疗
公开(公告)号：US20090220504A1
公开(公告)日：2009-09-03
申请号：US12293382
申请日：2007-03-21
申请人： Anan Chuntharapai , Gregory D. Plowman , Marc Tessier-Lavigne , Yan Wu , Weilan Ye
发明人： Anan Chuntharapai , Gregory D. Plowman , Marc Tessier-Lavigne , Yan Wu , Weilan Ye
IPC分类号： A61K39/395 , C07K16/28 , C07H21/00 , C12N15/63 , C12N5/00 , G01N33/53 , A61P35/00 , A61P37/00 , A61P27/02
CPC分类号： A61K39/3955 , A61K45/06 , A61K51/1093 , A61K2039/505 , A61K2039/507 , C07K16/22 , C07K16/2842 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/74
摘要： The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.
摘要翻译：本发明涉及VEGF拮抗剂和α5β1拮抗剂用于治疗癌症并抑制血管生成和/或血管通透性的用途，包括抑制疾病中的异常血管发生。本发明还涉及VEGFR激动剂和α5β1激动剂促进血管生成和血管通透性的用途。本发明还涉及新的抗α5β1抗体，包含它们的组合物和试剂盒以及制备和使用它们的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式